Navigation Links
Palatin Technologies, Inc. to Report Fiscal Year 2011 Fourth Quarter Results; Teleconference and Webcast to be held on September 22, 2011
Date:9/19/2011

CRANBURY, N.J., Sept. 19, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its fourth quarter, fiscal year 2011 financial results on Thursday, September 22, 2011 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 22, 2011, which will include discussion of the results of operations in greater detail and an update on corporate developments.Schedule for the Financial Results Press Release, Conference Call / WebcastQ4 & Fiscal Year 2011 Financial Results Press Release

9/22/2011 at 7:30 a.m. ETQ4 & Fiscal Year 2011 Conference Call-Live

9/22/2011 at 11:00 a.m. ETDomestic Dial-In Number

1-800-281-7970International Dial-In Number

1-913-312-0671Pass code

9488233Q4 & Fiscal Year 2011 Conference Call-Replay

9/22-9/29/2011Domestic Dial-In Number

1-888-203-1112International Dial-In Number

1-719-457-0820Pass code

9488233Webcast Live and Replay Access

http://www.palatin.com The webcast and replay can be accessed by logging on to the “Investor/Media Center-Webcasts”
section of Palatin’s website at http://www.palatin.com About Palatin Technologies, Inc.Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... NEW PROVIDENCE, N.J. , Sept. 2, 2014 /PRNewswire/ ... sponsor for MassBio,s 20th Annual Golf Classic, a major ... The event will be held on September 5 at ... Massachusetts . The MassBioEd Foundation ... through educational programs, workforce development, and lifelong ...
(Date:9/2/2014)... a billionth of a meter in size, are around ... benefit human health, as in some innovative early cancer ... viruses, air pollution, traffic emissions, cosmetics, sunscreen and electronics. ... St. Louis, led by Lan Yang, PhD, the Das ... Engineering, and their collaborators at Tsinghua University in China ...
(Date:9/2/2014)... including University of Oregon chemist Geraldine Richmond, have ... self-assembling, synthetic proteins called peptoid nanosheets that mimic ... -- detailed this week in a paper placed ... of the National Academy of Sciences -- ... the two-dimensional peptoid nanosheets that can be used ...
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... Market Study on Membrane Technology in Pharmaceutical, Biopharma and ... Witness Highest Growth by 2019" the global membrane technology market for ... 7,029.9 million in 2014 and is expected to grow ... to reach an estimated value of USD 10,886.0 million ...
Breaking Biology Technology:Linde helps fund STEM education in Massachusetts 2Linde helps fund STEM education in Massachusetts 3Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5
... ... ... var shortURL ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
... ... ... var shortURL = ""; BitlyCB.alertResponse ... grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in ...
... in a row, a pair of Rensselaer students took ... held by the American Society of Mechanical Engineers (ASME). ... Jaron Kuppers won top honors in the national competition ... process. The SET process offers a new method for ...
Cached Biology Technology:YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 2YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 3YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 4YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 5YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 6YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 7YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 8YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 9Medivir: R&D Day 2Medivir: R&D Day 3Medivir: R&D Day 4Medivir: R&D Day 5Medivir: R&D Day 6Medivir: R&D Day 7Medivir: R&D Day 8Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 2Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 3Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 4
(Date:9/2/2014)... Cancer Center researchers may have discovered a new way ... vulnerable by deficient DNA repair. , The findings were ... , The study, led by James E. Hansen, ... of Medicine, found that cancer cells with deficient DNA ... genetic damage) were significantly more vulnerable to attack by ...
(Date:9/2/2014)... FL, September 2, 2014 In a new study ... from the Florida campus of The Scripps Research Institute ... cells into unique manufacturing sites for molecules that can ... a cell as a reaction vessel and a disease-causing ... a diseased cell," said TSRI Professor Matthew Disney.,"Because the ...
(Date:9/2/2014)... sequence their genetic information. How is it possible ... parts of the body are so different? While every ... additional regulatory layer exists that determines which of the ... modifications of genome-bound histone proteins or the DNA itself ... top of the genetic information and is thus called ...
Breaking Biology News(10 mins):Sabotage as therapy: Aiming lupus antibodies at vulnerable cancer cells 2Scripps Florida scientists make diseased cells synthesize their own drug 2Throwing a loop to silence gene expression 2
... assessment of malnutrition, created by researchers at Penn State, ... diagnosis and treatment. Up to 50 percent of ... be malnourished, according to Gordon Jensen, professor and head ... confusion exists in the clinical community on how to ...
... seeking to refine and improve lung-cancer screening by combining a ... more effectively. The trial combines a CT chest scan and ... to build on recent research demonstrating that CT screening alone ... CT screening of high-risk patients can reduce lung-cancer deaths. But ...
... heel within our cells that bacteria are able to exploit ... their findings could lead to the development of new anti-infective ... resistance. University of Manchester researchers studied Listeria ... listeriosis in humans when digested and found they are ...
Cached Biology News:Researchers unveil new assessment for diagnosing malnutrition 2Trial seeks improved lung-cancer screening by combining imaging and biomarkers 2
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
... The Experion Pro260 analysis kit for 10 ... to perform protein analysis with the Experion ... Pro260 microfluidic chips, 3 x 520 microliters ... microliters Pro260 ladder (10-260 kD), 400 microliters ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Staccato Mini-Workstations provide fast and reliable ... proteomics and drug development laboratories. Staccato ... instrumentation to automate basic liquid handling ... are controlled with either Caliper's time ...
Biology Products: